One of the major challenges of the COVID-19 pandemic has been shortages, slow speed, and cost of diagnostics tests. The Lucks lab hopes to change that. In a collaborative effort, the Lucks, Jewett, Leonard, and Mangan labs were awarded a National Science Foundation Rapid Response Research (NSF RAPID) grant to develop inexpensive, point-of-use diagnostics for COVID-19. This technology would use CRISPR to detect the virus in nasal swabs, saliva samples, water sources, or on surfaces. After developing the initial platform, the goal is to commercial this technology through a collaboration with Stemloop, which was founded by former lab postdoc Khalid Alam.